权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a clinically relevant mouse model of ER+ breast cancer

ER乳腺癌临床相关小鼠模型的开发

基本信息

批准号：
10290139
负责人：
Zhe Li
金额：
$ 19.15万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-01 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10290139
关键词：
Address Adenoviruses Adult Affect Alleles Animal Model Animals Appearance Biogenesis Biology Breast Cancer cell line Breast Epithelial Cells CCND1 gene CCNE2 gene Cell Cycle Arrest Cell Cycle Progression Cell Lineage Cells Cessation of life Clinical Cyclin D1 DNA Sequence Alteration Deletion Mutation Dependence Development Disease ESR1 gene Ectopic Expression Engraftment Enhancers Estrogen Therapy Estrogen receptor positive Estrogens Event Exhibits Failure Female Genes Genetically Engineered Mouse Goals Hematopoietic Neoplasms Hematopoietic System Human Hyperactivity Immune response Immune system In Vitro Injections Keratin Knockout Mice Laboratories Lead Malignant Neoplasms Mammary Neoplasms Mammary Tumorigenesis Mesenchymal Metastatic breast cancer Metastatic to Mixed Neoplasm Modeling Mouse Mammary Tumor Virus Mus Mutate Mutation Oncogenic Organoids Pathway interactions Patients Phenotype Physiologic pulse Physiological Primary Neoplasm Process RB1 gene RUNX1 gene Recurrence Resistance development Ribosomes Signal Transduction Stress Study models Supplementation TP53 gene Testing Transplantation Woman Xenograft Model base breast tumorigenesis cancer cell cancer type carcinogenesis cell type clinically relevant conditional knockout cyclin E2 experience hormone therapy human cancer mouse model improved in vivo in vivo Model interest loss of function mutation malignant breast neoplasm mouse model neoplastic cell novel pre-clinical promoter standard care tool transcription factor tumor

项目摘要

The purpose of this proposed R21 project is to develop and validate a novel, clinically relevant mouse model for estrogen receptor-positive (ER+) breast cancer. Most human breast cancers are ER+ and are treated by endocrine therapy. Current clinical challenges for treating ER+ breast cancer include: 1) some patients do not respond to or develop resistance to endocrine therapy; 2) some patients eventually progress to ER+ metastatic breast cancer. Animal models that can faithfully recapitulate the biology of ER+ breast cancer are essential for addressing these challenges in a preclinical setting. However, current in vivo models are inadequate. It remains an unmet clinical need to more faithfully model ER+ breast cancer under the physiological setting. The failure to model ER+ breast cancer faithfully in animals (e.g., mice) may be due to: 1) oncogenic events are not targeted to the correct cellular origin; 2) oncogenic mutations specifically associated with human ER+ breast tumors are rarely modeled in mice. Taking these into consideration, we recently developed a new mouse model for ER+ breast cancer based on a recurrent genetic mutation uniquely found in human ER+ breast tumors, i.e., loss-of-function mutation or deletion of an estrogen/ER signaling- related transcription factor gene, RUNX1. The model is based on intraductal injection of a Cre-expressing adenovirus (Ad-Cre) under the control of the Keratin 8 promoter (Ad-K8-Cre) to female mice carrying conditional knockout alleles of Runx1 and p53. Ad-K8-Cre-induced loss of RUNX1 and p53 in K8+ luminal mammary epithelial cells (MECs) led to development of ER+ mammary tumors with hyperactive ribosome biogenesis and immune responses, which are also observed in human RUNX1-deficient ER+ breast cancers. However, since Ad-K8-Cre targets both ER+ and ER- luminal MECs and the resulting tumors exhibited features of both ER+ and Claudin-low (i.e., tumor cells with mesenchymal-like appearance) cancers, it is unclear whether the mixed tumor phenotype is due to their different cellular origins (e.g., ER+ vs. ER- luminal MECs) and/or due to p53-loss (which promotes cell fate plasticity). We hypothesize that in order to make this model more clinically relevant to human ER+ breast cancer, it can be further improved by inducing RUNX1- loss and its cooperating oncogenic events (i.e., other than p53-loss) specifically in ER+ luminal MECs (i.e., the potential cellular origin of ER+ breast cancer). To address this, two Specific Aims are proposed. Aim 1 will focus on developing a new Ad-Cre tool to specifically target Cre expression to the ER+ luminal sublineage, so that mammary tumorigenesis is initiated only from ER+ luminal cells. In Aim 2, we will test if oncogenic events affecting the RB-E2F pathway (as hyperactive ribosome biogenesis may lead to ribosomal stress, which may cause cell cycle arrest via this pathway) would cooperate with RUNX1-loss, leading to ER+ mammary tumors from luminal MECs. The successful development of such model would provide an invaluable tool for better understanding the biology and therapy of ER+ breast cancer.

这个拟议的R21项目的目的是开发和验证一种新的，临床相关的小鼠模型雌激素受体阳性（ER+）乳腺癌。大多数人乳腺癌是ER+，内分泌治疗目前治疗ER+乳腺癌的临床挑战包括：1）一些患者不对内分泌治疗有反应或产生耐药性; 2）一些患者最终进展为ER+ 转移性乳腺癌。可以忠实地概括ER+乳腺癌生物学的动物模型是对于在临床前环境中应对这些挑战至关重要。然而，目前的体内模型不足在乳腺癌模型下更忠实地建模ER+乳腺癌仍然是未满足的临床需求。生理环境未能在动物中忠实地建模ER+乳腺癌（例如，小鼠）可能是由于： 1)致癌事件不是针对正确的细胞起源; 2）致癌突变特异性与人ER+乳腺肿瘤相关的肿瘤很少在小鼠中建模。考虑到这些因素，我们最近开发了一种新的ER+乳腺癌小鼠模型，该模型基于一种独特的复发性基因突变，在人ER+乳腺肿瘤中发现，即，雌激素/ER信号传导的功能丧失突变或缺失- 相关转录因子基因RUNX 1。该模型是基于导管内注射表达Cr 在角蛋白8启动子（Ad-K8-Cre）的控制下，将腺病毒（Ad-Cre）转染至携带 Runx 1和p53的条件敲除等位基因。Ad-K8-Cre诱导的K8+细胞中RUNX 1和p53的丢失乳腺上皮细胞（MEC）导致ER+乳腺肿瘤的发展，具有高度活跃的核糖体生物发生和免疫应答，这也在人RUNX 1缺陷型ER+乳腺癌中观察到。然而，由于Ad-K8-Cre靶向ER+和ER-管腔MEC两者，并且所产生的肿瘤表现出与ER+和ER-管腔MEC的相似性。 ER+和紧密连接蛋白-低的特征（即，具有间充质样外观的肿瘤细胞）癌症，不清楚混合肿瘤表型是否是由于它们的不同细胞起源（例如，ER+与ER-管腔 MEC）和/或由于p53缺失（其促进细胞命运可塑性）。我们假设为了让这个在临床上与人ER+乳腺癌更相关的模型中，它可以通过诱导RUNX 1- 损失及其协同致癌事件（即，而不是p53-缺失）在ER+管腔MEC中特异性地表达（即， ER+乳腺癌的潜在细胞起源）。为此，提出了两个具体目标。要求1 将专注于开发一种新的Ad-Cre工具，以特异性地将Cre表达靶向ER+管腔亚系，因此乳腺肿瘤发生仅从ER+管腔细胞开始。在目标2中，我们将测试是否致癌影响RB-E2 F途径的事件（因为过度活跃的核糖体生物发生可能导致核糖体应激，这可能会导致细胞周期停滞通过这一途径）将与RUNX 1的损失，导致ER+ 来自管腔MEC的乳腺肿瘤。这种模式的成功发展将提供一个更好地了解ER+乳腺癌的生物学和治疗的宝贵工具。